$23.72
1.62% yesterday
Nasdaq, Nov 15, 10:13 pm CET
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

BridgeBio Pharma Inc Stock price

$23.72
-1.66 6.54% 1M
-6.25 20.85% 6M
-16.65 41.24% YTD
-5.80 19.65% 1Y
-24.44 50.75% 3Y
-4.54 16.07% 5Y
-3.83 13.90% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.39 1.62%
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

Key metrics

Market capitalization $4.48b
Enterprise Value $5.82b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 26.72
P/S ratio (TTM) P/S ratio 20.59
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2,209.77%
Revenue (TTM) Revenue $217.77m
EBIT (operating result TTM) EBIT $-532.70m
Free Cash Flow (TTM) Free Cash Flow $-451.54m
Cash position $405.73m
EPS (TTM) EPS $-2.41
P/E forward negative
P/S forward 20.59
EV/Sales forward 26.66
Short interest 14.08%
Show more

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a BridgeBio Pharma Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
88%
Hold
12%

Financial data from BridgeBio Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
218 218
2,209% 2,209%
100%
- Direct Costs 7.49 7.49
3% 3%
3%
210 210
9,635% 9,635%
97%
- Selling and Administrative Expenses 230 230
86% 86%
106%
- Research and Development Expense 506 506
22% 22%
233%
-526 -526
2% 2%
-242%
- Depreciation and Amortization 6.29 6.29
4% 4%
3%
EBIT (Operating Income) EBIT -533 -533
2% 2%
-245%
Net Profit -439 -439
28% 28%
-202%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Positive
Seeking Alpha
one day ago
BridgeBio Pharma, Inc.'s acoramidis is awaiting FDA's approval decision for transthyretin amyloidosis, with strong clinical data suggesting a likely approval and potential “blockbuster” status. The PDUFA date is 29th Nov. Despite past setbacks, including a Phase 3 failure, recent data shows significant improvements in survival rates and cardiovascular-related hospitalizations, bolstering the ap...
Neutral
GlobeNewsWire
11 days ago
- Case study co-authored by members of BridgeBio senior management and BridgeBio co-founder and MIT professor, Andrew W. Lo, Ph.D.
Neutral
Business Wire
17 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, has announced that the first patient has been dosed with BBO-10203 in the BREAKER-101 trial. BBO-10203 is a first-in-class orally bioavailable RAS:PI3Ka breaker that blocks the interaction betw...
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Neil Kumar
Employees 550
Founded 2015
Website www.bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today